Benitec Biopharma
BNTC
30 hedge funds and large institutions have $240M invested in Benitec Biopharma in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 4 reducing their positions, and 3 closing their positions.
275% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 4
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
89% more capital invested
Capital invested by funds: $127M → $240M (+$113M)
20% more funds holding
Funds holding: 25 → 30 (+5)
48.06% less ownership
Funds ownership: 129.88% → 81.82% (-48%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$23.1M |
| 2 |
Janus Henderson Group
London,
|
+$18.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$12.2M |
| 4 |
BlackRock
New York
|
+$1.57M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$5.65M |
| 2 |
AC
Armistice Capital
New York
|
-$551K |
| 3 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
-$434K |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$274K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$134K |
BNTC Hedge Fund Activity: Q4 2024 in Review
30 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2024, worth a combined $240M — up 89% from $127M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BNTC positions and 3 closed out — a net gain of 5 holders — while 15 added to existing stakes and 4 trimmed.
The largest buyer was Franklin Resources, adding an estimated $23.1M. The largest seller was AWM Investment Company, cutting an estimated $5.65M.
- 30 institutional investors held Benitec Biopharma (BNTC) as of Q4 2024, up from 25 in Q3 2024.
- Funds reported $240M of Benitec Biopharma stock for Q4 2024, up 89% quarter-over-quarter.
- 8 funds opened new Benitec Biopharma positions in Q4 2024 and 3 closed out, a net change of +5 holders.
- The largest Benitec Biopharma buyer in Q4 2024 was Franklin Resources, an estimated $23.1M added.
- The largest Benitec Biopharma seller in Q4 2024 was AWM Investment Company, an estimated $5.65M sold.
Based on aggregated 13F filings for Q4 2024.